dr. becerra on ribociclib/letrozole in er /her2- breast cancer
Published 8 years ago • 1.8K plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
7:14
ribociclib for hr advanced breast cancer
-
7:21
fda approval of ribociclib for metastatic breast cancer
-
0:59
dr. kelly on the fda approval of ribociclib in hr breast cancer
-
1:39
frontline endocrine therapies and ribociclib in early stage hr her2- breast cancer
-
1:11
using ribociclib in the first-line setting
-
2:49
safety and efficacy of ribociclib and letrozole in advanced breast cancer – the monaleesa-2 trial
-
1:58
recent fda approval of ribociclib as upfront therapy
-
1:19
monaleesa-2: improved os seen in hr advanced breast cancer treated with ribociclib letrozole
-
1:26
ribecca: ribociclib, a cdk4/6 inhibitor in er breast cancer
-
3:11
a correlative analysis of coralleen: preoperative ribociclib letrozole vs chemo in hr /her2- bc
-
1:05
dr. richard finn on pd 0332991 plus letrozole in er-positive breast cancer
-
1:40
early ribecca results: ribociclib with letrozole for metastatic breast cancer
-
2:35
dr. burris on updated monaleesa-2 trial results for hr breast cancer
-
1:29
monaleesa-2: ribociclib letrozole in pts with de novo metastatic disease and late recurrence
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors
-
3:08
adding ribociclib to endocrine therapy shows an improvement in invasive dfs in hr /her2 bc patients
-
2:00
ribociclib in early breast cancer | nejm
-
2:46
right choice: ribociclib et vs combo chemo in aggressive hr /her2− advanced breast cancer
-
1:41
adapt trial: endocrine ribociclib vs. chemotherapy in hr /her2- early breast cancer